PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Negative revenue growth while AXSM stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-148.93%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.41%
Negative EBIT growth while AXSM is at 2.39%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.41%
Negative operating income growth while AXSM is at 2.39%. Joel Greenblatt would press for urgent turnaround measures.
-24.71%
Negative net income growth while AXSM stands at 2.60%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-23.33%
Negative EPS growth while AXSM is at 3.23%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-23.33%
Negative diluted EPS growth while AXSM is at 3.23%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.68%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
89.77%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
79.09%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-5123.81%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
89.73%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
77.51%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1605.51%
Positive growth while AXSM is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-64.94%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
48.08%
Positive short-term equity growth while AXSM is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-26.37%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
15.04%
R&D growth drastically higher vs. AXSM's 4.56%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
33.15%
We expand SG&A while AXSM cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.